Commentary · 8 Apr 2026
Conference abstractPublished 20 Oct 2014
Small change, big difference: The discovery of drug candidate for anti-Schistosomiasis japonicum
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
S chistosomiasis is a relatively neglected tropical disease and it has long been a major public health problem in China and other subtropical countries. Reported by WHO, of the five species of schistosome, schistosomiasis caused by S. japonicum leads to more serious health damages and it is the most difficult one to be prevented. Not only does S. japonicum have an obvious difference on ecology and biology with other schistosomes, but also it has more complex transmission links and epidemic factors. Over the past decades, chemotherapy is the main strategy of schistosomiasis control. Praziquantel (PZQ) is currently the first choice of drug for treatment of Schistosoma mansoni and Schistosoma haematobium infection and is the only drug for treatment of S. japonicum infection. However, PZQ-resistance has been confirmed, therapeutic dose in China mainland has been increased from 40 mg/kg/one time to 60 mg/kg/two times currently. Especially, deficiency of praziquantel (PZQ) due to its low efficiency to juvenile stages of schistosome caused the endless of Schistosomiasis. The Schistosomiasis will never disappear even after PZQ has been used in clinic for almost 40 years. In present study, three praziquantel analogues with asymmetric cycle were synthesized for biological antischistosomal tests. Compound 2 was developed as drug lead for its excellent activity against juvenile stages of S. japonicum both in vitro and in vivo on mice and rabbits with low cytotoxicity and no drug resistance, which could be a good drug candidate to make up the deficiency of PZQ and benefit PZQ action mechanism elucidation
Subjects
ToxicologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Toxicology.
Perspective · 25 Feb 2026
Toxicological and Health Effects: Mechanisms, Exposure Routes and Prevention Strategies
Case report · 23 Feb 2026
Case Report: Methaemoglobinaemia Following Indoxacarb Ingestion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Toxicology
- SubjectToxicology
- BylineArticles whose byline prints “De-Qun Sun”
